Schedule a Call Back
The ideal scenario involves a collaborative approach
where the industry works closely with regulators to co-create policies that
balance innovation with compliance, ensuring that AI and automation drive
positive health outcomes without compromising ethical standards, says Sudipta Ghosh, Partner, PwC India.
What regulatory challenges do
you see in the adoption of AI and automation in the pharma industry?
Regulatory challenges in AI and automation within the pharma
industry primarily revolve around compliance, data security, transparency, and
ethical considerations. The industry is heavily regulated, with agencies like
the FDA (U.S.), EMA (Europe), and others requiring strict adherence to
standards for patient safety, data integrity, and validation processes.
Integrating AI and automation into this framework poses several challenges:
· Data privacy and
security: Given that AI systems rely on vast datasets, often containing
sensitive patient information, ensuring data privacy and compliance with
regulations like GDPR (Europe) or HIPAA (U.S.) is crucial. AI algorithms need
to handle this data securely while adhering to data anonymisation and
encryption protocols.
· Validation and
explainability: Regulatory bodies demand transparency in the decision-making
process of AI algorithms, which requires the technology to be explainable and
interpretable. Black-box AI models are often unsuitable for pharma because
their decision-making processes can’t easily be justified. There is a need for
robust validation methodologies to ensure these systems' accuracy and
reliability.
· Ethical AI and bias: AI algorithms must be
designed to avoid bias, ensuring that they do not make decisions that could
adversely affect specific patient groups. Regulatory guidelines are now pushing
for frameworks that minimise bias in AI models, especially in clinical trials
and patient treatment recommendations.
· Compliance with
evolving standards: AI technology evolves rapidly, outpacing the development of
regulatory standards. This gap creates uncertainty for pharmaceutical companies
on how to deploy AI innovations while staying compliant. Constant engagement
with regulators to shape policies that accommodate these technological advances
is critical.
What role do you think
government funding should play in advancing AI and automation in
pharmaceuticals?
Government funding plays a pivotal role in catalysing AI and
automation within the pharmaceutical sector. Investments in this area can lead
to breakthroughs in drug discovery, manufacturing efficiencies, and healthcare
accessibility. Key areas where government funding could have the most impact
include:
· Research and
Development (R&D): Government-backed grants and funding initiatives can
support collaborative R&D projects between academia, AI tech firms, and
pharma companies. This would accelerate innovations in AI-driven drug discovery
and personalised medicine, reducing the time and cost involved in bringing new
drugs to market.
· Infrastructure
development: The adoption of AI and automation requires significant investment
in digital infrastructure, data centers, and high-performance computing.
Government funding in this area can lower the entry barriers for smaller
companies and startups in the pharmaceutical ecosystem.
· Training and
upskilling: To address the growing need for AI and data science talent in
pharma, government-sponsored training programs and AI research centers can play
a vital role. This would not only prepare the workforce for future challenges
but also ensure the industry is equipped with professionals who understand both
pharma and AI technologies.
· Public-Private
Partnerships (PPP): Governments should encourage PPPs where tech companies and
pharmaceutical firms collaborate on AI and automation projects. These
collaborations can de-risk investments for private players while ensuring
public health interests are safeguarded.
What are the potential
implications of AI and automation on quality assurance, drug pricing, and
accessibility?
The implementation of AI and automation in the pharmaceutical
sector has far-reaching implications for quality assurance, drug pricing, and
accessibility:
· Quality Assurance
(QA):
AI-powered predictive analytics can significantly enhance QA by predicting
potential defects in drug manufacturing processes and ensuring consistency in
production. Machine learning algorithms can analyse large datasets to detect
anomalies in real time, reducing the risk of human error and ensuring that only
high-quality products reach the market.
· Drug pricing: Automation in
production processes can lower manufacturing costs by increasing efficiency and
reducing waste. AI algorithms can optimise supply chains, manage inventories,
and predict demand, all of which contribute to cost reductions. These savings
can be passed on to consumers, potentially lowering drug prices and making
essential medications more affordable.
· Accessibility: AI can play a
transformative role in increasing the accessibility of drugs, especially in
developing countries. By optimising distribution networks and predicting the
demand for specific drugs in various regions, AI systems can ensure that
medications reach underserved areas more effectively. Additionally, AI can aid
in developing personalised treatment plans, improving patient outcomes and
healthcare delivery in remote regions.
How do you view the balance
between industry self-regulation and government oversight?
Balancing industry self-regulation with government oversight is
crucial in driving AI adoption in pharma without stifling innovation. Here's a
nuanced perspective:
· Self-regulation: The pharmaceutical
industry should proactively adopt ethical AI principles and best practices to
guide its AI and automation initiatives. Creating industry-wide standards for
AI model development, validation, data handling, and risk management can foster
trust among stakeholders and accelerate regulatory approval processes. This
proactive approach also positions companies as responsible innovators, leading
the way in the ethical use of AI.
· Government oversight: While self-regulation
is essential, there must be a robust framework of government oversight to
ensure patient safety, data integrity, and fair market practices. Regulatory
bodies should focus on creating flexible, outcome-based guidelines that
encourage innovation while setting clear boundaries to prevent misuse.
Governments could also set up regulatory sandboxes for pharma companies to test
AI solutions in controlled environments, allowing for faster iterations and
refinement of their technologies.
The ideal scenario involves a collaborative
approach where the industry works closely with regulators to co-create policies
that balance innovation with compliance, ensuring that AI and automation drive
positive health outcomes without compromising ethical standards.
What strategies do you
recommend for addressing workforce displacement?
Workforce displacement is a significant concern as automation and
AI technologies become more pervasive in the pharma industry. The key to
addressing this challenge lies in a combination of proactive workforce
development and creating new job roles:
· Reskilling and
upskilling programs: Companies should invest in comprehensive training programs to
help their workforce transition into roles that require more analytical and
technical skills. Reskilling initiatives should focus on areas such as data
science, AI model management, and digital operations in pharmaceutical
settings. Government incentives for reskilling programs can further enhance
these efforts.
· Human-AI
collaboration: Rather than replacing jobs, the focus should be on augmenting
human capabilities with AI tools. For example, automating routine tasks in
clinical trials or drug manufacturing allows professionals to focus on
strategic decision-making, complex problem-solving, and innovation.
· Creating new job
roles:
The rise of AI in the pharma industry will lead to new job roles that didn’t
exist before, such as AI ethics officers, data governance specialists, and
automation strategists. Companies should work with educational institutions to
align curricula with industry needs, ensuring a steady supply of talent for
these emerging roles.
Cyient emphasised that this investment reflects its commitment to driving innovation in the semiconductor industry.
Read moreIn this interview with Sanskriti Ramachandran, Sanjeev Dharwadkar, CEO, Pharma Tech Consulting LLP, explores the intersection of AI and pharma in today's world.
Read moreIndustry 5.0 signifies a shift from prioritising economic value to generating societal value, emphasising overall well-being rather than just welfare.
Read morePro-Med Instruments (P) Ltd offers a wide range of programmable controllers - PCD-33A Series.
Arihant Packing & Gasket Company offers a wide range of gasket graphite powder.
Asahi Kasei, a leading resin and compounding technology provider, has initiated the sales of 3D printing (3DP) filaments in North America through Asahi Kasei Plastics North America (APNA). The soft la Read more
INDUSTRIAL PRODUCTS FINDER (IPF) is India’s only industrial product portal. Referred to as the ‘Bible’ of the manufacturing sector in India,
INDUSTRIAL PRODUCTS FINDER (IPF) is India’s only industrial product portal. Referred to as the ‘Bible’ of the manufacturing sector in India,
Hi There!
Now get regular updates from IPF Magazine on WhatsApp!
Click on link below, message us with a simple hi, and SAVE our number
You will have subscribed to our Industrial News on Whatsapp! Enjoy
Schedule a Call Back